CTOs on the Move

Health Choice Network

www.hcnetwork.org

 
Health Choice Network (HCN) is a national model of a successful collaboration of community health centers (CHCs) and one of several HRSA-sponsored Health Center Controlled Networks. HCN is addressing health care disparities, providing health information technologies and strengthening the financial position of the community health care system. Founded in 1994 as a 501c(3) organization, HCN was created and is governed by its members who comprise a minority-based Board of Directors. Network members maintain their vital community orientation by retaining their local-governing, consumer-majority Boards of Directors. Community Health Centers that own and control the Network operate more efficiently, can deliver care ...
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details
Maylee Sanchez
 Chief Information Officer Profile

Similar Companies

Talcomp

Talcomp is a Houston, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Domio

Create the most delightful experiences for our guests. We believe we can positively change the way people think about alternative lodging. The process begins by seeking out high-quality homes with modern spaces and prime locations, to ensure our designers can bring out the natural beauty of each property and to give you an authentic travel experience. We deck out each Domio with curated furniture, accessories and artwork to create a distinguished level of style and comfort, and provide round-the-clock concierge services for your convenience. With Domio, feel at home anywhere in the world.

ARMO BioSciences

Armo Biosciences is a company based out of 1630 Channing Ave, Palo Alto, California, United States.

Themis Vision Systems

Themis Vision Systems is a Stennis Space Center, MS-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

MSI

MSI Methylation Sciences Inc. (“MSI”) is a clinical-stage pharmaceutical company focused on developing new products based on molecules which have clinical proof of concept but which have yet to be exploited in the major pharmaceutical markets. MSI`s focus is in the CNS space where clinical proof of concept is key to reducing the drug development risk. Our lead product candidate, Strada™, is based upon Ademetionine, a naturally occurring molecule produced throughout the body, where it plays a vital role in the one-carbon cycle. Our disease indication is Major Depressive Disorder (MDD).